All In Biotech

Drug Trial Radar · NCT06915025

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jul 9, 2025

Primary completion

Oct 31, 2032

Study completion Oct 31, 2032

Sponsor

Lead sponsor
ImunonIndustry
Sponsor type
Industry
First posted
Apr 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Conditions

  • Epithelial Ovarian Cancer
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma

Interventions

  • IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)Drug

    100 mg/m2 IP given weekly during frontline treatment

  • PaclitaxelDrug

    175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment

  • CarboplatinDrug

    AUC 6 IV given every 21 days for 6 cycles during frontline treatment

  • OlaparibDrug

    Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.

  • NiraparibDrug

    Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut \& HRD/BRCAwt.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 48 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Advent Health

    Orlando, Florida · Recruiting

  • Louisiana State University HSC - NO Cancer Center

    New Orleans, Louisiana · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • Providence Cancer Institute

    Portland, Oregon · Recruiting

  • Sanford Health

    Sioux Falls, South Dakota · Recruiting

  • Erlanger Health

    Chattanooga, Tennessee · Recruiting

  • Providence Sacred Heart Medical Center & Children's Hospital

    Spokane, Washington · Recruiting

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.